-
Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021
-
View Affiliations Hide AffiliationsRegina Selbselbr rki.de
-
View Citation Hide Citation
Citation style for this article: . Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021. Euro Surveill. 2021;26(31):pii=2100616. https://doi.org/10.2807/1560-7917.ES.2021.26.31.2100616 Received: 18 Jun 2021; Accepted: 03 Aug 2021
- Previous Article
- Table of Contents
- Next Article
Abstract
We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Full text loading...